Objective: To describe local experience in managing an outbreak of Candida auris in a tertiary-care setting.

Methods: In response to emerging Candida auris, an outbreak investigation was conducted at our hospital between March 2018 and June 2019. Once a patient was confirmed to have Candida auris, screening of exposed patients and healthcare workers (HCWs) was conducted. Postexposure screening included those who had had direct contact with or shared the same unit or ward with a laboratory-confirmed case. In response to the increasing number of cases, new infection control measures were implemented.

Results: In total, 23 primary patients were detected over 15 months. Postexposure screening identified 11 more cases, and all were patients. Furthermore, ~28.6% of patients probably caught infection in another hospital or in the community. Infection control measures were strictly implemented including hand hygiene, personal protective equipment, patient hygiene, environmental cleaning, cohorting of patients and HCWs, and avoiding the sharing of equipment. The wave reached a peak in April 2019, followed by a sharp decrease in May 2019 and complete clearance in June 2019. The case patients were equally distributed between intensive care units (51.4%) and wards (48.6%). More infections (62.9%) occurred than colonizations (37.1%). Urinary tract infection (42.9%) and candidemia (17.1%) were the main infections. In total, 7 patients (20.0%) died during hospitalization; among them, 6 (17.1%) died within 30 days of diagnosis.

Conclusions: Active screening of exposed patients followed by strict infection control measures, including environmental cleaning, was successful in ending the outbreak. Preventing future outbreaks is challenging due to outside sources of infection and environmental resistance.

Download full-text PDF

Source
http://dx.doi.org/10.1017/ice.2020.414DOI Listing

Publication Analysis

Top Keywords

candida auris
12
infection control
12
control measures
12
june 2019
8
screening exposed
8
patients
8
exposed patients
8
postexposure screening
8
environmental cleaning
8
infection
6

Similar Publications

Microspheres based on galactomannan and Spondias purpurea L. extract to increase antifungal and antibiofilm efficacy against Candida spp.

Int J Biol Macromol

January 2025

Laboratory of Polymers and Materials Innovation, Department of Organic and Inorganic Chemistry, Sciences Center, Federal University of Ceará, Campus of Pici, Zip Code 60440-900 Fortaleza, CE, Brazil. Electronic address:

The ongoing problem of an increasing resistance of Candida spp. to available antifungals, has made it necessary the search for new therapeutic alternatives. The aim of this work was to develop a microsphere based on Caesalpinia ferrea galactomannan and Spondias purpurea L.

View Article and Find Full Text PDF

A Novel and Robust Method for Investigating Fungal Biofilm.

Bio Protoc

January 2025

Laboratory of Protein Translation and Fungal Pathogenesis, Regional Centre for Biotechnology, Faridabad, India.

, labeled an urgent threat by the CDC, shows significant resilience to treatments and disinfectants via biofilm formation, complicating treatment/disease management. The inconsistencies in biofilm architecture observed across studies hinder the understanding of its role in pathogenesis. Our novel in vitro technique cultivates biofilms on gelatin-coated coverslips, reliably producing multilayer biofilms with extracellular polymeric substances (EPS).

View Article and Find Full Text PDF

The First Case of Detection and Infection Control in a Pediatric Bone Marrow Transplant Child Patient in Guangxi, China.

Infect Drug Resist

January 2025

Department of Laboratory Medicine, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, People's Republic of China.

is an emerging yeast species and an opportunistic pathogen. Due to its multi-drug resistance and ability to colonize and transmit, it poses a significant risk for outbreaks in medical institutions. In this study, we report the first case of detected in a pediatric bone marrow transplant child patient in Guangxi, China.

View Article and Find Full Text PDF

Recently expanded reports of multidrug-resistant fungal infections underscore the need to develop new and more efficient methods for antifungal drug discovery. A ubiquitous problem in natural product drug discovery campaigns is the rediscovery of known compounds or their relatives; accordingly, we have integrated Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) for structural dereplication and Yeast Chemical Genomics for bioprocess evaluation into a screening platform to identify such compounds early in the screening process. We identified 450 fractions inhibiting and the resistant strains of and among more than 40,000 natural product fractions.

View Article and Find Full Text PDF

The Candida Genome Database (CGD; www.candidagenome.org) is unique in being both a model organism database and a fungal pathogen database.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!